Clinical Trials Logo

Filter by:
NCT ID: NCT04239768 Completed - Face Skin Laxity Clinical Trials

Efficacy of an Antiage Aesthetic Treatment for the Middle and Inferior Third of the Face

Start date: October 14, 2019
Phase: N/A
Study type: Interventional

Primary endpoint of the study is to evaluate clinically and by non-invasive instrumental evaluations the aesthetic performance, on the third middle and inferior of the face, of "MonoDermà HA Bio-revitalizing gel", an intradermal filler containing hyaluronic acid, combined to a low level laser therapy (LLLT) to obtain a stable photo-cross-linking effect inside the dermis.

NCT ID: NCT04239014 Withdrawn - Ovarian Cancer Clinical Trials

A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.

DUETTE
Start date: August 7, 2020
Phase: Phase 2
Study type: Interventional

To investigate the effectiveness and tolerability of a second maintenance treatment in participants with platinum-sensitivity relapsed (PSR) epithelial ovarian cancer, who have previously received PARPi maintenance treatment and who have benefit (complete response [CR] or partial response [PR]) or stable disease (SD) from further platinum based chemotherapy.

NCT ID: NCT04238988 Recruiting - Clinical trials for Locally Advanced Cervical Cancer

Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer

MITO CERV 3
Start date: February 18, 2021
Phase: Phase 2
Study type: Interventional

Single arm multicenter phase II trial evaluating the role of Pembrolizumab in combination to Carboplatin-Paclitaxel chemotherapy in locally advanced cervical cancer patients.

NCT ID: NCT04238819 Active, not recruiting - Clinical trials for Refractory Solid Tumor

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Start date: November 9, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The study's purpose is to see if the drug, abemaciclib, is safe and effective when given with other drugs to kill cancer cells. The study is open to children and young adults with solid tumors, including neuroblastoma, that did not respond or grew during other anti-cancer treatment. For each participant, the study is estimated to last up to 2 years.

NCT ID: NCT04238390 Withdrawn - Clinical trials for Bacteremia Caused by Gram-Negative Bacteria

Ceftolozane-tazobactam Versus Meropenem for ESBL and AmpC-producing Enterobacterales Bloodstream Infection

MERINO III
Start date: January 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether ceftolozane-tazobactam is as effective as meropenem with respect to 30 day mortality in the treatment of bloodstream infection due to third-generation cephalosporin non-susceptible Enterobacterales or a known chromosomal AmpC-producing Enterobacterales (Enterobacter spp., Citrobacter freundii, Morganella morganii, Providencia spp. or Serratia marcescens).

NCT ID: NCT04238221 Not yet recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Effect of add-on Doxofylline on Lung Function in Stable COPD

EDAI
Start date: September 1, 2020
Phase: Phase 4
Study type: Interventional

It is a phase IV, prospective, interventional, single blind, randomized, crossover trial in which the investigators will evaluate the effects of a 4-week treatment with doxofylline 400 mg bid, in add-on to maximal inhalation therapy, in clinically stable COPD patients.

NCT ID: NCT04238000 Recruiting - Parkinson Disease Clinical Trials

Cerebellar rTMS Theta Burst for Dual-task Walking in Parkinson's Disease

Start date: January 1, 2018
Phase: N/A
Study type: Interventional

Objective of the study: To test the efficacy of theta burst cerebellar stimulation on dual task walking in Parkinson's disease using a cross-over design and wearing sensors technology Design: Twenty Parkinson's disease patients with no dementia will be recruited for a cross-over sham-controlled study. Each patient will undergo a sham stimulation or a single session of cerebellar theta burst stimulation with a wash out period of at least 14 days. Each patient will be evaluated before and after stimulation by a battery of gait and movement tests using wearing sensors technology .

NCT ID: NCT04237948 Completed - Clinical trials for Progressive Supranuclear Palsy

tDCS Plus Physical Therapy for Progressive Supranuclear Palsy

Start date: January 1, 2018
Phase: N/A
Study type: Interventional

Objective of the study: To test the efficacy of cerebellar transcranial direct current stimulation (tDCS) associated with physical rehabilitation on postural instability and falls in progressive supranuclear palsy using a double-blind design and wearing sensors technology Design: Twenty probable PSP patients with no dementia and still able to walk will be recruited for a randomized double-blind sham-controlled study. Each patient will be hospitalized for a four week physical rehabilitation. In the real-arm, the patients will undergo a ten cerebellar tDCS stimulations while the placebo arm will undergo sham stimulation. Each patient will be evaluated before and after stimulation by PSP-rating scale (PSP-RS), cognitive tests and a battery of gait and movement tests using wearing sensors technology.

NCT ID: NCT04237662 Recruiting - Clinical trials for Periodontal Diseases

Enamel Matrix Derivatives & Periodontal Therapy in Diabetic Patients

PERIOEMD-4
Start date: January 1, 2021
Phase: N/A
Study type: Interventional

The aim of this study is to compare periodontal treatment with or without the adjunct of an enamel matrix derivative in terms of periodontal healing in diabetic patients.

NCT ID: NCT04237649 Terminated - Solid Tumors Clinical Trials

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors

Start date: February 20, 2020
Phase: Early Phase 1
Study type: Interventional

The primary objective of the trial was to characterize the safety, tolerability, and maximum tolerated dose (MTD)/recommended dose (RD) for expansion of single agent KAZ954 and KAZ954 in combination with PDR001, NIR178 and NZV930.